Optimal Serotype Compositions for Pneumococcal Conjugate Vaccination under Serotype Replacement

PLoS Computational Biology

Volumn 10, Issue 2, 2014, Pages

  Nurhonen, Markku ^a   Auranen, Kari ^a  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASES; UNCERTAINTY ANALYSIS;

ADVERSE EFFECT; AGE GROUPS; DISEASE INCIDENCE; FINLAND; OLDER POPULATION; PREDICTIVE MODELS; QUANTITATIVE TOOL; READY TO USE; SEQUENTIAL ALGORITHM; SEROTYPES;

VACCINES;

PNEUMOCOCCUS VACCINE; VACCINE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; CHILD; CLASSIFICATION ALGORITHM; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; FINLAND; HUMAN; INFORMATION STORAGE; MATHEMATICAL COMPUTING; PNEUMOCOCCAL INFECTION; PRESCHOOL CHILD; PROCESS OPTIMIZATION; PROGNOSIS; SEROTYPE; VACCINATION; VIRUS CARRIER; ALGORITHM; BIOLOGICAL MODEL; BIOLOGY; CLASSIFICATION; HETEROZYGOTE; IMMUNOLOGY; INCIDENCE; PNEUMOCOCCAL INFECTIONS; PREVENTION AND CONTROL; SEROTYPING; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME;

ALGORITHMS; CARRIER STATE; CHILD; CHILD, PRESCHOOL; COMPUTATIONAL BIOLOGY; FINLAND; HUMANS; INCIDENCE; MODELS, IMMUNOLOGICAL; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; SEROTYPING; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME; VACCINES, CONJUGATE;

EID: 84895745256     PISSN: 1553734X     EISSN: 15537358     Source Type: Journal    
DOI: 10.1371/journal.pcbi.1003477     Document Type: Article

References (22)

1. Pilishvili T, Lexau C, Farley MM, Hadler J, Harrison LH, et al. (2010) Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 201: 32-41 10.1086/648593; 10.1086/648593.
2. Miller E, Andrews NJ, Waight PA, Slack MP, George RC, (2011) Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: An observational cohort study. Lancet Infect Dis 11: 760-768 10.1016/S1473-3099(11)70090-1; 10.1016/S1473-3099(11)70090-1.
3. Weinberger DM, Malley R, Lipsitch M, (2011) Serotype replacement in disease after pneumococcal vaccination. Lancet 378: 1962-1973 10.1016/S0140-6736(10)62225-8; 10.1016/S0140-6736(10)62225-8.
4. Flasche S, Van Hoek AJ, Sheasby E, Waight P, Andrews N, et al. (2011) Effect of pneumococcal conjugate vaccination on serotype-specific carriage and invasive disease in England: A cross-sectional study. PLoS Med 8: e1001017 10.1371/journal.pmed.1001017; 10.1371/journal.pmed.1001017.
5. Hanage WP, Finkelstein JA, Huang SS, Pelton SI, Stevenson AE, et al. (2010) Evidence that pneumococcal serotype replacement in Massachusetts following conjugate vaccination is now complete. Epidemics 2: 80-84 10.1016/j.epidem.2010.03.005; 10.1016/j.epidem.2010.03.005.
6. Feikin DR, Kagucia EW, Loo JD, Link-Gelles R, Puhan MA, et al. (2013) Serotype-specific changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: A pooled analysis of multiple surveillance sites. PLoS Med 10: e1001517 10.1371/journal.pmed.1001517; 10.1371/journal.pmed.1001517.
7. Melegaro A, Choi YH, George R, Edmunds WJ, Miller E, et al. (2010) Dynamic models of pneumococcal carriage and the impact of the heptavalent pneumococcal conjugate vaccine on invasive pneumococcal disease. BMC Infect Dis 10: 90-2334-10-90 10.1186/1471-2334-10-90; 10.1186/1471-2334-10-90.
8. Nurhonen M, Cheng AC, Auranen K, (2013) Pneumococcal transmission and disease in silico: A microsimulation model of the indirect effects of vaccination. PLoS One 8: e56079 10.1371/journal.pone.0056079; 10.1371/journal.pone.0056079.
9. Bottomley C, Roca A, Hill PC, Greenwood B, Isham V, (2013) A mathematical model of serotype replacement in pneumococcal carriage following vaccination. J R Soc Interface 10: 20130786 10.1098/rsif.2013.0786; 10.1098/rsif.2013.0786.
10. Shea KM, Weycker D, Stevenson AE, Strutton DR, Pelton SI, (2011) Modeling the decline in pneumococcal acute otitis media following the introduction of pneumococcal conjugate vaccines in the US. Vaccine 29: 8042-8048 10.1016/j.vaccine.2011.08.057; 10.1016/j.vaccine.2011.08.057.
11. Weinberger DM, Harboe ZB, Flasche S, Scott JA, Lipsitch M, (2011) Prediction of serotypes causing invasive pneumococcal disease in unvaccinated and vaccinated populations. Epidemiology 22: 199-207 10.1097/EDE.0b013e3182087634; 10.1097/EDE.0b013e3182087634.
12. Weinberger DM, Bruden DT, Grant LR, Lipsitch M, O'Brien KL, et al. (2013) Using pneumococcal carriage data to monitor postvaccination changes in invasive disease. Am J Epidemiol 178: 1488-1495 10.1093/aje/kwt156; 10.1093/aje/kwt156.
13. Yildirim I, Hanage WP, Lipsitch M, Shea KM, Stevenson A, et al. (2010) Serotype specific invasive capacity and persistent reduction in invasive pneumococcal disease. Vaccine 29: 283-288 10.1016/j.vaccine.2010.10.032; 10.1016/j.vaccine.2010.10.032.
14. Syrjanen RK, Kilpi TM, Kaijalainen TH, Herva EE, Takala AK, (2001) Nasopharyngeal carriage of streptococcus pneumoniae in Finnish children younger than 2 years old. J Infect Dis 184: 451-459 10.1086/322048.
15. Palmu A, Kaijalainen T, Verho J, Herva E, Mäkelä PH, et al. (2002) Long-term efficacy of the sevenvalent PncCRM vaccine on nasopharyngeal carriage [Abstract 24]. In: Abstracts of the 3rd International Symposium on Pneumococci and Pneumococcal Diseases (ISSPD); 5-9 May 2002; Anchorage, Alaska, United States.
16. Leino T, Hoti F, Syrjanen R, Tanskanen A, Auranen K, (2008) Clustering of serotypes in a longitudinal study of streptococcus pneumoniae carriage in three day care centres. BMC Infect Dis 8: 173-2334-8-173 10.1186/1471-2334-8-173; 10.1186/1471-2334-8-173.
17. Park IH, Pritchard DG, Cartee R, Brandao A, Brandileone MC, et al. (2007) Discovery of a new capsular serotype (6C) within serogroup 6 of Streptococcus pneumoniae. J Clin Microbiol 45: 1225-1233 10.1128/JCM.02199-06.
18. Park IH, Moore MR, Treanor JJ, Pelton SI, Pilishvili T, et al. (2008) Differential effects of pneumococcal vaccines against serotypes 6A and 6C. J Infect Dis 198: 1818-1822 10.1086/593339.
19. Spijkerman J, Prevaes SM, van Gils EJ, Veenhoven RH, Bruin JP, et al. (2012) Long-term effects of pneumococcal conjugate vaccine on nasopharyngeal carriage of S. pneumoniae, S. aureus, H. influenzae and M. catarrhalis. PLoS One 7: e39730 10.1371/journal.pone.0039730; 10.1371/journal.pone.0039730.
20. Huang SS, Hinrichsen VL, Stevenson AE, Rifas-Shiman SL, Kleinman K, et al. (2009) Continued impact of pneumococcal conjugate vaccine on carriage in young children. Pediatrics 124: e1-11 10.1542/peds.2008-3099; 10.1542/peds.2008-3099.
21. Croucher NJ, Finkelstein JA, Pelton SI, Mitchell PK, Lee GM, et al. (2013) Population genomics of post-vaccine changes in pneumococcal epidemiology. Nat Genet 45: 656-663 10.1038/ng.2625; 10.1038/ng.2625.
22. Skinner JM, Indrawati L, Cannon J, Blue J, Winters M, et al. (2011) Pre-clinical evaluation of a 15-valent pneumococcal conjugate vaccine (PCV15-CRM197) in an infant-rhesus monkey immunogenicity model. Vaccine 29: 8870-8876 10.1016/j.vaccine.2011.09.078; 10.1016/j.vaccine.2011.09.078.